ARASENS Trial Videos - Results from #20

ARASENS Trial Videos

Search

ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith Details Joining Alicia Morgans is Matthew Smith to discuss the ARASENS trial presented at GU ASCO 2022. ARASENS is a randomized phase 3 trial of darolutamide versus placebo in combination with docetaxel and androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Smith believes that the ARASENS data strongly supports a three-drug regimen of ADT, docetaxel, and an AR...
Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 - Oliver Sartor Details Oliver Sartor joins Alicia Morgans to reflect on prostate cancer data presented during ASCO GU, highlighting data from three studies. Dr. Sartor discusses the phase 3 ARASENS trial, the phase 3 MAGNITUDE study, and the phase 3 PROpel trial. They discuss their perspectives on how these data will inform practice in the future. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Dire...
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi Details Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...